Icahn sells Genzyme stock

Carl Icahn has cashed in his Genzyme chips and evidently gone looking for another game. After arousing intense speculation last year that he would pull an Icahn and shake up Genzyme with big demands and blistering criticism--as he had at ImClone and other biotechs--Icahn sold his shares in late December. Genzyme CEO Henri Termeer (photo) may have persuaded Icahn to take the money and run after publicly vowing to resist any effort to make him sell or break up the aggressive developer. "We have pioneered very important therapies and that is what we want to continue to do," he told the hometown Boston Globe late last year.

Of course, whatever his long-range goals may have been, Icahn still came out well ahead. Genzyme stock had shot up 20 percent when he cashed out its 1.5 million shares.

- check out this article for more

Suggested Articles

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.

Scientists at Sanford Burnham Prebys suggested that inhibiting the PPP1R1B protein could be a new strategy for treating pancreatic cancer.